Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 11/20 | 0.52 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | PDE1A | P54750 | 2/20 | 0.44 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.44 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30731296 | 1.00 | NPBWR1 (0.52) | NPBWR1MCHR1ALDH1A1MAPTLMNA | |
| SCHEMBL21796911 | 0.84 | NPBWR1 (0.48) | NPBWR1MCHR1ALDH1A1MAPTLMNA | |
| SCHEMBL29071647 | 0.84 | NPBWR1 (0.48) | NPBWR1MCHR1ALDH1A1MAPTLMNA | |
| SCHEMBL30487302 | 0.84 | NPBWR1 (0.48) | NPBWR1MCHR1ALDH1A1MAPTLMNA | |
| SCHEMBL24265692 | 0.80 | RECQL (0.56) | ALDH1A1MAPTLMNASMN1; SMN2HPGD | |
| SCHEMBL22553999 | 0.80 | CNR2 (0.55) | NPBWR1MCHR1ALDH1A1MAPTLMNA | |
| SCHEMBL30731305 | 0.80 | CNR2 (0.55) | NPBWR1MCHR1ALDH1A1MAPTLMNA | |
| SCHEMBL16014396 | 0.80 | NPBWR1 (0.52) | NPBWR1MCHR1ALDH1A1MAPTLMNA | |
| SCHEMBL30468608 | 0.80 | NPBWR1 (0.52) | NPBWR1MCHR1ALDH1A1MAPTLMNA | |
| SCHEMBL22892720 | 0.79 | NPBWR1 (0.51) | NPBWR1MCHR1ALDH1A1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11919902-B2 | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors | HIBERCELL, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| CN-108137510-B | Compound (I) | 葛兰素史密斯克莱知识产权发展有限公司 | 2021-07-20 | — | — | CN | disclosed |
| US-10975081-B2 | Substituted fused pyrazole compounds and their use as LRRK2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-04-13 | — | — | US | disclosed |
| US-10975081-B2 | Substituted fused pyrazole compounds and their use as LRRK2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-04-13 | — | — | US | disclosed |
| EP-3325449-B1 | HETEROCYCLIC COMPOUNDS, PARTICULARLY PYRIMIDINYLINDAZOLE COMPOUNDS FOR TREATING PARKINSON'S DISEASE | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-01-13 | — | — | EP | disclosed |
| EP-3325449-B1 | HETEROCYCLIC COMPOUNDS, PARTICULARLY PYRIMIDINYLINDAZOLE COMPOUNDS FOR TREATING PARKINSON'S DISEASE | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-01-13 | — | — | EP | disclosed |
| EP-3728230-A1 | ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | Ravenna Pharmaceuticals, Inc. (US) | 2020-10-28 | — | — | EP | disclosed |
| US-20200331913-A1 | ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | HIBERCELL, INC. | 2020-10-22 | — | — | US | disclosed |
| US-20200331913-A1 | ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | HIBERCELL, INC. | 2020-10-22 | — | — | US | disclosed |
| US-20200079777-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-03-12 | — | — | US | disclosed |
| EP-2847193-B1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2019-08-07 | — | — | EP | disclosed |
| US-20190031685-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2019-01-31 | — | — | US | disclosed |
| US-9951088-B2 | D2 receptor modulators and methods of use thereof in the treatment of diseases and disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2018-04-24 | — | — | US | disclosed |
| EP-2847193-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2015-03-18 | — | — | EP | disclosed |
| US-20150072974-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2015-03-12 | — | — | US | disclosed |
| WO-2013169964-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2013-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331913-A1 | ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | PIP5K1A, PIP5K1B, PIP5K1C | NPBWR1 2798/4885MCHR1 4024/4885ALDH1A1 4524/4885 |
| US-20150072974-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, SNCA, KYNU | NPBWR1 4109/4885MCHR1 972/4885ALDH1A1 726/4885 |
| US-10975081-B2 | Substituted fused pyrazole compounds and their use as LRRK2 inhibitors | LRRK2, PARK7, PINK1 | NPBWR1 4663/4885MCHR1 4466/4885ALDH1A1 3655/4885 |
| US-11919902-B2 | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors | PIP5K1A, PIP5K1B, PIP5K1C | NPBWR1 2798/4885MCHR1 4024/4885ALDH1A1 4524/4885 |
| US-20200079777-A1 | COMPOUNDS | LRRK2, PARK7, PINK1 | NPBWR1 4561/4885MCHR1 4625/4885ALDH1A1 3623/4885 |
| US-20190031685-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, SNCA, KYNU | NPBWR1 4109/4885MCHR1 972/4885ALDH1A1 726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.